Respiratory[autotexts]

Bronchiectasis / Consultation template

New bronchiectasis patient

First assessment: the history that points at a cause, the severity markers, and the treatable traits worth finding early.

Fills in order
  1. 1Referred with
  2. 2Duration of cough
  3. 3Daily sputum
  4. 4Blood in the sputum
  5. 5Breathlessness, MRC
  6. 6Chest pain, fatigue, fevers, weight loss
  7. 7Antibiotics in the last 12 months
  8. 8Childhood pneumonia, whooping cough, mea…
  9. 9Recurrent sinus or ear infection since c…
  10. 10Infertility or situs inversus
  11. 11Neonatal respiratory distress
  12. 12Rheumatoid arthritis or other connective…
  13. 13Inflammatory bowel disease
  14. 14Reflux, swallowing difficulty or recurre…
  15. 15aspergillosis
  16. 16Smoking and occupational exposure

and 31 more, in the block below.

Paste block 47 fields
Referred with: []

History:
Duration of cough: []
Daily sputum: [volume, colour when well, colour when unwell]
Blood in the sputum: [never, streaking, or frank, and how often]
Breathlessness, MRC [1 to 5]
Chest pain, fatigue, fevers, weight loss: []
Exacerbations in the last 12 months: [number, and how many needed
intravenous antibiotics or admission]
Antibiotics in the last 12 months: []

Points to a cause:
Childhood pneumonia, whooping cough, measles or tuberculosis: []
Recurrent sinus or ear infection since childhood: []
Infertility or situs inversus: []
Neonatal respiratory distress: []
Rheumatoid arthritis or other connective tissue disease: []
Inflammatory bowel disease: []
Reflux, swallowing difficulty or recurrent aspiration: []
Previous or current asthma, and any history of allergic bronchopulmonary
aspergillosis: []
Smoking and occupational exposure: []
Immunosuppressive treatment, past or present: []
Family history of bronchiectasis, cystic fibrosis or immunodeficiency: []

Current treatment:
Airway clearance: [technique, taught by whom, how often actually done]
Nebulised or inhaled treatment: []
Inhaled corticosteroid, and the indication for it: []
Long-term antibiotic: []
Vaccination: [influenza, pneumococcal, COVID-19]

Examination:
SpO2 []% on air   Height [] cm   Weight [] kg   BMI []
[crackles, wheeze, clubbing, nasal disease]

Investigations:
CT chest: [lobes involved, traction bronchiectasis or cystic change, mucus
plugging, tree-in-bud]
Sputum culture including mycobacteria: []
Spirometry: FEV1 [] L ([]%), FVC [] L, ratio []%
Aetiology screen: [see the bronchiectasis test bundle]

Severity:
Bronchiectasis Severity Index [] or FACED []
Chronic Pseudomonas aeruginosa infection: [yes or no]

Impression:
Bronchiectasis affecting [], with [] exacerbations per year, [chronic
infection with organism or no chronic infection], cause [established or under
investigation].

Plan:
1. Referral to respiratory physiotherapy for airway clearance: []
2. Aetiology screen: [sent, awaited]
3. Sputum for culture and mycobacteria: []
4. Vaccination brought up to date: []
5. Pulmonary rehabilitation if exercise-limited: []
6. Self-management plan and exacerbation antibiotic plan: []
7. Review in [] months with [sputum, spirometry]

How to use it

Two questions decide most of what happens next: how often does this person exacerbate, and what grows in their sputum. Chronic Pseudomonas infection and a high exacerbation rate are what move someone from airway clearance alone to long-term macrolides or inhaled antibiotics, so both belong in the first letter. Airway clearance is the first line of the plan rather than the last because it is the intervention with the strongest recommendation behind it and the one most often left to a leaflet. Send sputum for mycobacterial culture at the outset: non-tuberculous mycobacterial infection changes the whole management, and long-term macrolide monotherapy started in undiagnosed NTM disease breeds resistance and closes off treatment later.

Why it says that

None of this is in the copied text. It is here so you can check the block against its source, and change it when the source changes.

Trials behind it

  • ASPEN 2025 Brensocatib cut exacerbations by about 20% — the first drug licensed specifically for bronchiectasis
  • PROMIS 2024 Inhaled colistimethate reduced exacerbations in one trial and not in its replicate
  • BAT 2013 Maintenance azithromycin roughly halved the proportion of patients having any exacerbation
  • BLESS 2013 Erythromycin modestly cut exacerbations, including in Pseudomonas-infected patients, at the cost of increased macrolide resistance
  • EMBRACE 2012 Azithromycin cut exacerbations by 62% without improving lung function or quality of life

Records on respiratorytrials.org.